Abstract: Chagas disease is a neglected pathology responsible for about 12,000 deaths every year across Latin America. Although six million people are infected by the Trypanosoma cruzi, current therapeutic options are limited, highlighting the need for new drugs. Here we report the preliminary structure activity relationships of a small library of 17 novel pyridyl sulfonamide derivatives. Analogues 4 and 15 displayed significant potency against intracellular amastigotes with EC50 of 5.4 µM and 8.6 µM. In cytotoxicity assays using mice fibroblast L929 cell lines, both compounds indicated low toxicity with decent selectivity indices (SI) >36 and >23 respectively. Hence these compounds represent good starting points for further lead optimization. 2 Chagas disease (CD) is a parasitic infection caused by the protozoan Trypanosoma cruzi (T. cruzi). This neglected disease is endemic to 21 countries across Latin America with more than six million people infected worldwide. A further 70 million people are at risk of infection and approximately 12,000 deaths annually are associated with CD. 1 CD has become an important public health concern in other non-endemic countries across North America, Europe and Asia because of globalization mainly due to the migration of infected individuals to these areas. [2] [3] CD treatment is based on two nitroheterocyclic drugs: nifurtimox (Nf) and benznidazole (Bz), both introduced in clinics more than 50 years ago. 4 These nitroderivatives require long administration periods and produce adverse side effects, which may result in the discontinuation of the treatment by 20-30% of the patients. Furthermore, there are several naturally resistant strains and very low cure rates (≤ 20 %) once the disease reaches chronic phase. [5] [6] Two inhibitors of the ergosterol biosynthetic route Posaconazole and E1224 (a pro-drug of ravuconazole) were recently evaluated in clinical trials on chronic chagasic patients.
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Unfortunately, both failed to sustain high therapeutic cure rates after one year of follow up despite promising results in experimental murine and canine models of T. cruzi infection. [7] [8] Also, the recently concluded clinical trial BENEFIT, revealed that Bz is not able to impair or reduce the progression of the chagasic cardiomyopathy when administered to chronic patients, despite the remarkable reduction of the parasite load assessed through qPCR. 9 Those findings emphasize the importance of pre-clinical studies to investigate the biological activity of novel molecules against T. cruzi, aiming to find new alternative treatments that are more tolerable, potent, orally adequate, with broader efficacy, lower costs and reduced administration periods. 10 Presently, we have identified a 3-pyridyl sulfonamide derivative (compound 1) active against T. cruzi from a high throughput screening of a small set of 100 diverse compounds based on our previous study. 11 Compound 1 showed an EC50 (minimal concentration able to reduce the infection index by 50%) of 5.5 µM against intracellular forms of T. cruzi (Silvio X10/7 strain), with minimal toxicity to the mammalian hosts (Vero cell line), and comparable activity to nifurtimox, with EC50 of 0.9 µM (Figure 1 ). As a part of the project related to Chagas disease drug discovery that recommends testing against different parasite strains and forms relevant for mammalian infection (intracellular and bloodstream forms), compound 1 was selected as a lead compound due to its low toxic profile, drug likeness (Lipinski's rule of five) and synthetic accessibility. A small set of 16 analogues (2-17) were purchased (Table 1) to establish the initial structure activity relationships (SARs). As a part of SAR development, compounds (Supporting information)
were selected based on various modifications that differ in steric properties (naphthyl Vs phenyl), location of nitrogen on the pyridyl ring (2 nd , 3 rd and 4 th position), alkyl chain length (methoxy, ethoxy and propoxy substituents) and extent of branching (methyl, ethyl, isopropyl and tertiary butyl). Compounds with methylene linker were also selected and parameters such as the EC50 values against the intracellular parasites were taken into consideration while establishing the SARs.
Next, regarding the phenotypic biological analysis, the novel analogs were initially assayed using a fixed concentration (10 µM) that corresponds to the EC90 of Bz. The non-infected cells (controls) were treated with DMSO. Analogues that reached similar or higher activity than Bz were further evaluated in assays with increasing concentrations (serially diluted) for the determination of the EC50. In both assays, the cultures were maintained at 37 ºC for 96 h. 12 When compound 1 was further screened against intracellular forms of T. cruzi but now against Tulahuen strain using Bz as reference drug, the lead compound with 3-pyridyl moiety and 4-ethoxy naphthyl ring A displayed lower activity than Bz (Table 1) , but sustained a low toxicity profile against other cell line (L929 cells reaching LC50 > 400). When a small set of analogues (2-4) was screened to investigate the contribution of pyridyl moiety towards the anti-T.cruzi activity we found that the replacement of 3-pyridyl moiety from compound 1 (EC50 >25 µM) either with 4-pyridyl (2) or 2-substituted pyridyl (3) moieties did not improve the potency of the compounds towards the intracellular forms (see Table 1 regarding the % of reduction levels using a fixed concentration of 10 µM). These results suggest that the position of the nitrogen on the pyridyl ring is not relevant for the anti-parasitic activity.
Replacement of 4-ethoxy naphthyl ring A in compound 1 with 6-methoxy naphthyl ring C (4 in Table 1 ) resulted in over 5-fold increase in potency (EC50 of ~5.44 µM). This suggests that the substitution pattern of the naphthyl ring is important for activity. Sulfonamide derivatives 1-17 (Table 1) were further evaluated for their toxicity on mouse fibroblast cell lines NTCL clone 929 (L929). The cell cultures were incubated with increasing concentrations of the compounds 1-17 and host cell viability assessed through colorimetric assays using AlamarBlue for determining the LC50 that corresponds to the compound concentration reducing viability by 50%. 12 The ratio of LC50 and EC50 values is reported as Selectivity Index (SI) in Table 1 . In general, all these compounds showed an excellent in vitro safety profile, with no toxicity noticed until 200 µM. Although benznidazole showed the higher selectivity index (SI) value (> 114), among the sulfonamide analogs, compound 4 with 6-methoxy naphthyl ring substitution displayed better selectivity with SI value >36.
Compounds 15, 7 and 5 displayed moderate selectivity with SI values >23, >15, and >13.5 respectively (Table 1) .
Overall four analogues (4, 5, 7 and 15) of compound 1 showed activity against intracellular forms of T.cruzi. Compound 4 is the most potent with EC50 of ~ 5.44 µM. These compounds were further analysed using bloodstream trypomastigotes (BT -Y strain, DTU II) obtained by cardiac puncture from Swiss Webster mice during the parasitemia peak. 13 As the heart is an important target organ for T.cruzi infection and inflammation, the toxicity upon cardiac cells was evaluated using heart samples of Swiss Webster mice embryos as reported by Meirelles et al. 13 Uninfected cardiac cell cultures were incubated for 24 h with different concentrations of these compounds and then cell viability assessed with PrestoBlue for determination of the LC50 values. 14 All four compounds did not induce loss of cellular viability after incubation for 24 h with concentrations up to 100 µM, whereas reference compound (Bz) showed LC50 > 1000 µM. After 24 h of incubation at 37 ⁰C, all compounds did not show trypanocidal effect against BT up to 50 µM, while Bz potency was 11 µM ( Table 2) .
Study of overall pharmacokinetic compliance of the active compounds.
In silico studies were carried out to predict the pharmacokinetic (PK) characteristics. Computational assessment of PK properties for the novel drug candidates at early stages of drug discovery programmes has gained importance as experimental determination of these properties using in vivo models is costly and time consuming. This information is widely used to refine the PK properties at the early stage of lead identification or lead optimization. 15 In silico prediction of the drug likeness and pharmacokinetic properties of five active sulfonamide compounds (Table 3) was carried out using the QikProp module of Schrodinger and admetSAR. 16 Recommended compliance scores for the PK properties 17 are used to assess the drug likeliness of these compounds. All showed compliance to the "Rule of five" 18 and "Rule of three". [19] [20] Hence these compounds could show good aqueous solubility (within the recommended range), and excellent permeability (greater than 500) properties. Good Greater values of QPPMDCK indicates higher cell permeability. 21 All active compounds displayed good QPPMDCK values and are thus likely to show good blood brain permeation.
QPlogKhsa values are the prediction of ability of the compounds to bind to human serum albumin. All the active compounds displayed compliance to the recommended values, indicating that these compounds would have lower binding to serum albumin and the unbound fraction could have access to the putative receptor drug target. In recent years hERG screening has been introduced earlier in drug discovery program. 22 Human ether-a-go-go related gene (HERG) encodes a potassium ion (K+) channel that is implicated in the fatal arrhythmia. If a drug molecule blocks the potassium ion (K+) channel then it develops the risk of heart failure. Hence HERG potassium channel blockers are potentially toxic. 23 The recommended compliance score for blockage of HERG K+ channels is > −5. Compound 15 showed an acceptable level (log HERG -3.64) of HERG inhibition. Compounds 1, 4, 7 and 5 displayed marginal levels of HERG inhibition. Furthermore, all compounds are predicted to be non-mutagenic and non-carcinogenic (Table 3) .
Literature data reported the promising trypanocidal effect of sulfonamides in in vitro studies suggesting the importance of this chemical group as a scaffold for the development of new anti-T.cruzi agents. 24 Also, aromatic/heterocyclic sulfonamides incorporating halogeno/methoxyphenacetamido tails were able to inhibit the α-carbonic anhydrase of T.cruzi, being less effective against the human off target isoforms, but not active against in vivo infection in animal models. 25 The use of Nano emulsion oil formulation increased the effects upon T. cruzi probably due to an enhancement of the compounds permeation, suggesting that this type of formulation may lead to novel therapeutic approaches against this neglected disease. 26 It has also been reported that benzenesulfonylhydrazone (BS-H) and N-propionylbenzene sulfonylhydrazone (BS-NAH) derivatives displayed anti-trypanosomal activity against the NINOA and INC-5 strains of T.cruzi which are endemic in Mexico. This suggests that aryl sulfonyl derivatives has potential trypanocidal activity against different strains of T.cruzi. 27 As a part of our anti-trypanosomal drug development strategy, we have previously reported a study involving parallel evaluation of arylimidamide derivatives for their efficacy and ADMET properties 28 . This strategy has resulted in compounds with submicromolar trypanocidal activity and provided a better understanding of their drug likeness and pharmacokinetic properties at the early stage of our lead optimization process.
We are adopting a similar strategy in our sulfonamide lead optimisation studies. Our present phenotypic data, especially upon intracellular forms, demonstrate that 3-pyridyl sulfonamide compound (4) and pyridin-4-yl-methylsulfonamide (15) derivative are potential lead compounds for the development of novel anti-Trypanosoma cruzi drugs. The reported results should be useful in guiding future efforts to develop compounds with increased potency and maintaining the lower toxicity profile against mammalian hosts. Currently synthesis programme is underway in our laboratory to design and develop pyridyl sulfonamides as potential drug like candidates targeting T. cruzi.
